Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Litton

Showing results (21-30 of 166) with videos related to

Pageof 17
Sort By:
Toxicology|June 14, 2002
A comparison of Haber's rule at different ages using a physiologically based pharmacokinetic (PBPK) model for chloroform in ratsM V Evans, W K Boyes, J E Simmons, et al.
Cancer|February 24, 2012
Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancerShaheenah Dawood, Xiudong Lei, Jennifer K Litton, et al.
Clinical Breast Cancer|October 9, 2012
Impact of body mass index on survival outcome among women with early stage triple-negative breast cancerShaheenah Dawood, Xiudong Lei, Jennifer K Litton, et al.
Journal of Clinical Pharmacology|May 30, 2020
Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA TrialYanke Yu, Mohamed Elmeliegy, Jennifer K Litton, et al.
Cancer|October 29, 2024
Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapyHelen M Johnson, Juhee Song, Carla L Warneke, et al.
NPJ Breast Cancer|February 2, 2018
Characterization of bone only metastasis patients with respect to tumor subtypesAmanda Parkes, Katherine Clifton, Aydah Al-Awadhi, et al.
Cancer|August 7, 2007
Multifocal breast cancer in women < or =35 years oldJennifer K Litton, Yesim Eralp, Ana M Gonzalez-Angulo, et al.
Cancer|July 29, 2010
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancersCatherine M Kelly, Savitri Krishnamurthy, Giampaolo Bianchini, et al.
The Oncologist|June 17, 2016
Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation CarriersHaley Streff, Jessica Profato, Yuanqing Ye, et al.
Journal of Clinical Pharmacology|May 30, 2020
Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO TrialsMohamed Elmeliegy, Yanke Yu, Jennifer K Litton, et al.
Pageof 17

Showing results (21-30 of 166) with videos related to

Sort By:
Pageof 17
Toxicology|June 14, 2002
A comparison of Haber's rule at different ages using a physiologically based pharmacokinetic (PBPK) model for chloroform in ratsM V Evans, W K Boyes, J E Simmons, et al.
Cancer|February 24, 2012
Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancerShaheenah Dawood, Xiudong Lei, Jennifer K Litton, et al.
Clinical Breast Cancer|October 9, 2012
Impact of body mass index on survival outcome among women with early stage triple-negative breast cancerShaheenah Dawood, Xiudong Lei, Jennifer K Litton, et al.
Journal of Clinical Pharmacology|May 30, 2020
Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA TrialYanke Yu, Mohamed Elmeliegy, Jennifer K Litton, et al.
Cancer|October 29, 2024
Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapyHelen M Johnson, Juhee Song, Carla L Warneke, et al.
NPJ Breast Cancer|February 2, 2018
Characterization of bone only metastasis patients with respect to tumor subtypesAmanda Parkes, Katherine Clifton, Aydah Al-Awadhi, et al.
Cancer|August 7, 2007
Multifocal breast cancer in women < or =35 years oldJennifer K Litton, Yesim Eralp, Ana M Gonzalez-Angulo, et al.
Cancer|July 29, 2010
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancersCatherine M Kelly, Savitri Krishnamurthy, Giampaolo Bianchini, et al.
The Oncologist|June 17, 2016
Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation CarriersHaley Streff, Jessica Profato, Yuanqing Ye, et al.
Journal of Clinical Pharmacology|May 30, 2020
Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO TrialsMohamed Elmeliegy, Yanke Yu, Jennifer K Litton, et al.
Pageof 17